ERBB3 and breast carcinoma: Heterotrimerization of erbB3/erbB2/IGF-IR blocked trastuzumab binding and activated PI3K/AKT signaling pathway and Src kinase, which resulted in trastuzumab resistance in breast cancer cells[30].